KATHERYN FINDLAY: Open Payments
NPI 1104533363 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,482 in 130 payments from 25 companies in 2025. Trend: 2023 $567 · 2024 $1,562 · 2025 $2,482
Food & beverage: $2,482
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $309 |
| Corcept Therapeutics | 10 | $283 |
| GlaxoSmithKline, LLC. | 14 | $225 |
| Axsome Therapeutics, Inc. | 7 | $222 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $207 |
| AstraZeneca Pharmaceuticals LP | 7 | $166 |
| Kowa Pharmaceuticals America, Inc. | 8 | $143 |
| Lilly USA, LLC | 11 | $137 |
| Exact Sciences Corporation | 6 | $130 |
| Novo Nordisk Inc | 6 | $129 |
Products named: Korlym, Auvelity, XIFAXAN, VRAYLAR, ZORYVE, TRELEGY ELLIPTA, MOUNJARO, Cologuard Collection Kit.
Industry payments across TX — which companies pay providers there.
